O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors

Suradej Hongeng, Thomas P. Brent, Robert A. Sanford, Hao Li, Larry E. Kun, Richard L. Heideman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6- methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.

Original languageEnglish (US)
Pages (from-to)2459-2463
Number of pages5
JournalClinical Cancer Research
Volume3
Issue number12 I
StatePublished - Dec 1 1997

Fingerprint

Protein Methyltransferases
Brain Neoplasms
Methyltransferases
Central Nervous System Neoplasms
Pediatrics
DNA
Glioma
Primitive Neuroectodermal Tumors
Ependymoma
Medulloblastoma
Guanine
Alkylation
DNA Repair
Western Blotting
O-(6)-methylguanine
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hongeng, S., Brent, T. P., Sanford, R. A., Li, H., Kun, L. E., & Heideman, R. L. (1997). O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clinical Cancer Research, 3(12 I), 2459-2463.

O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. / Hongeng, Suradej; Brent, Thomas P.; Sanford, Robert A.; Li, Hao; Kun, Larry E.; Heideman, Richard L.

In: Clinical Cancer Research, Vol. 3, No. 12 I, 01.12.1997, p. 2459-2463.

Research output: Contribution to journalArticle

Hongeng, S, Brent, TP, Sanford, RA, Li, H, Kun, LE & Heideman, RL 1997, 'O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors', Clinical Cancer Research, vol. 3, no. 12 I, pp. 2459-2463.
Hongeng S, Brent TP, Sanford RA, Li H, Kun LE, Heideman RL. O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clinical Cancer Research. 1997 Dec 1;3(12 I):2459-2463.
Hongeng, Suradej ; Brent, Thomas P. ; Sanford, Robert A. ; Li, Hao ; Kun, Larry E. ; Heideman, Richard L. / O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 12 I. pp. 2459-2463.
@article{5a18de41678c439b8a4a922f37eed036,
title = "O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors",
abstract = "Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6- methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.",
author = "Suradej Hongeng and Brent, {Thomas P.} and Sanford, {Robert A.} and Hao Li and Kun, {Larry E.} and Heideman, {Richard L.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "2459--2463",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12 I",

}

TY - JOUR

T1 - O6-methylguanine-DNA methyltransferase protein levels in pediatric brain tumors

AU - Hongeng, Suradej

AU - Brent, Thomas P.

AU - Sanford, Robert A.

AU - Li, Hao

AU - Kun, Larry E.

AU - Heideman, Richard L.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6- methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.

AB - Chloroethylnitrosoureas (CENUs) are commonly used in the treatment of pediatric and adult central nervous system (CNS) tumors. The antitumor activity of CENUs has been hypothesized to be due to an alkylation occurring at the O6-position of guanine in DNA. The DNA repair protein O6- methylguanine-DNA methyltransferase (MGMT) is responsible for the repair of these potentially cytotoxic lesions and may underlie tumor resistance to CENUs. The current study is the largest report of MGMT levels among newly diagnosed pediatric CNS tumors and the only study that has quantitated MGMT by both biochemical and Western immunoblot assays. Our results show a good correlation between the two methods (r = 0.66). Medulloblastoma/primitive neuroectodermal tumor and ependymoma had the highest level of MGMT, followed by high-grade glioma and low-grade glioma. These data may provide a guide to the use of CENUs in the treatment of pediatric CNS tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031292579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031292579&partnerID=8YFLogxK

M3 - Article

C2 - 9815647

AN - SCOPUS:0031292579

VL - 3

SP - 2459

EP - 2463

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12 I

ER -